References
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
- Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
- James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
- Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
- Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7: 387–397.
- Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459–468.
- Bacher U, Haferlach T, Kern W, et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 2005;84:250–257.
- Diez-Martin JL, Graham DL, Petitt RM, et al. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 1991;66:287–299.
- Gangat N, Strand J, Lasho TL, et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008;80:197–200.
- Lawler SD. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera. Clin Haematol 1980;9:159–74.
- Rege-Cambrin G, Mecucci C, Tricot G, et al. A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 1987;25:233–245.
- Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988;72:386–395.
- Testa JR, Kanofsky JR, Rowley JD, et al. Karyotypic patterns and their clinical significance in polycythemia vera. Am J Hematol 1981;11:29–45.
- Andrieux JL, Demory JL. Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep 2005;4:224–229.
- McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006;20:168–171.
- Reilly JT. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia. 2008;22:1818–27.
- Aliano S, Cirmena G, Garuti A, et al. HMGA2 overexpression in polycythemia vera with t(12;21)(q14;q22). Cancer Genet Cytogenet 2007;177:115–119.
- Sever M, Kantarjian H, Pierce S, et al. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol 2009;90:522–525.
- Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007;138:354–358.
- Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755–761.
- Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24: 1574–1579.